MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock, net of...
$7,803,453
Net cash provided by
financing activities
$7,324,385
Canceled cashflow
$479,068
Net increase in cash
$171,841
Canceled cashflow
$7,152,544
Payment of financing
costs related to chef...
$465,200
Proceeds from exercise
and modification of...
-$13,868
Accounts payable
$1,540,535
Prepaid expenses and
other current assets
-$805,527
Financing costs related to
chef purchase...
$520,200
Incentive tax receivable
-$164,685
Acquired in-process
research and development
$114,399
Accrued expenses and
other current...
$66,118
Share-based compensation
$60,395
Amortization of operating
lease right-of-use...
$58,777
Other assets
-$7,766
Depreciation
$7,669
Non-cash financing costs
$3,044
Net cash used in
operating activities
-$7,140,544
Net cash used in
investing activities
-$12,000
Canceled cashflow
$3,349,115
Net loss
-$10,427,632
Purchases of in-process
research and development
$12,000
Operating lease liability
-$62,027
Back
Back
Cash Flow
source: myfinsight.com
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Sonnet BioTherapeutics Holdings, Inc. (SONN)